This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 49/2/322    most recent 01.HYP.0000253061.30170.68v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pilbrow, A. P. Articles by Cameron, V. A. Search for Related Content PubMed PubMed Citation Articles by Pilbrow, A. P. Articles by Cameron, V. A. Pubmed/NCBI databases Gene GEO Profiles HomoloGene UniGene Compound via MeSH Substance via MeSH Hazardous Substances DB (L)-METHIONINE Medline Plus Health Information Heart Failure Related Collections Clinical genetics Congestive

(Hypertension. 2007;49:322.)
© 2007 American Heart Association, Inc.

Original Articles

Angiotensinogen M235T and T174M Gene Polymorphisms in Combination Doubles the Risk of Mortality in Heart Failure

Anna P. Pilbrow; Barry R. Palmer; Chris M. Frampton; Tim G. Yandle; Richard W. Troughton; Elizabeth Campbell; Lorraine Skelton; John G. Lainchbury; A. Mark Richards; Vicky A. Cameron

From the Cardioendocrine Research Group, Department of Medicine, Christchurch School of Medicine and Health Sciences, Christchurch, New Zealand.

Correspondence to Vicky Cameron, Cardioendocrine Research Group, Department of Medicine, Christchurch School of Medicine and Health Sciences, 2 Riccarton Avenue, PO Box 4345, Christchurch 8140, New Zealand. E-mail vicky.cameron{at}chmeds.ac.nz

Angiotensinogen M235T and T174M polymorphisms have individually been associated with elevated levels of plasma angiotensinogen, hypertension, and left ventricular hypertrophy. In this study, heart failure patients (n=451) were genotyped for the angiotensinogen M235T and T174M polymorphisms to investigate association with survival (recorded over 4 years of follow-up) and prognostic hormone markers. Patients carrying the 235TT genotype (n=86) were 3 years younger at admission (P=0.011), and, in those with hypertension, diagnosis was made 10 years earlier than other patients. Patients carrying 1 174M allele (n=94) were more likely to have a previous history of heart failure (P=0.044) and increased mortality during follow-up (risk ratio: 1.69, 95% CI: 1.03 to 2.79; P=0.038) compared with 174TT homozygotes (n=355), despite having a higher left ventricular ejection fraction (P=0.009). "High-risk" genotype combinations (defined a priori as 235TT and/or 1 174M allele; n=144; 32%) were independently predictive of mortality, conferring a 2-fold greater risk of dying during the follow-up period (odds ratio: 2.0; 95% CI: 1.3 to 3.0; P=0.001). This study suggested that angiotensinogen gene variants M235T and T174M may provide prognostic information for long-term survival in heart failure patients.

Key Words: angiotensinogen • polymorphism • single nucleotide • mortality • heart failure • congestive • association

This article has been cited by other articles:

				P.-a. B. Shih and D. T. O'Connor Hereditary Determinants of Human Hypertension: Strategies in the Setting of Genetic Complexity Hypertension, June 1, 2008; 51(6): 1456 - 1464. [Full Text] [PDF]

				M. D. Littlejohn, B. R. Palmer, A. M. Richards, C. M. Frampton, A. P. Pilbrow, R. W. Troughton, V. A. Cameron, and M. A. Kennedy Ile164 variant of {beta}2-adrenoceptor does not influence outcome in heart failure but may interact with {beta} blocker treatment Eur J Heart Fail, January 1, 2008; 10(1): 55 - 59. [Abstract] [Full Text] [PDF]